GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Total Current Liabilities

2seventy bio (2seventy bio) Total Current Liabilities : $59.8 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. 2seventy bio's total current liabilities for the quarter that ended in Dec. 2023 was $59.8

2seventy bio Total Current Liabilities Historical Data

The historical data trend for 2seventy bio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Total Current Liabilities Chart

2seventy bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 103.40 75.87 98.39 79.79 59.78

2seventy bio Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.79 76.93 66.90 68.01 59.78

2seventy bio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

2seventy bio's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=24.444+12.66
+Other Current Liabilities+Current Deferred Liabilities
=7.272+15.403
=59.8

2seventy bio's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=24.444+12.66
+Other Current Liabilities+Current Deferred Liabilities
=7.272+15.403
=59.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

2seventy bio Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

2seventy bio (2seventy bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Total Current Liabilities
Comparable Companies
CARM PLX CDXS TALS ABSI PEPG DSGN ADAP CTXR TRVI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.2seventybio.com
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Lin Wei director C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938